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ABSTRACT
Background. Fluorescence-based techniques are powerful and valuable tools for studying biological 
materials. Fluorescence spectroscopy is one of these techniques which measures autofluorescence from 
a sample containing components such as proteins. The aim of this study was to evaluate the influence of 
deep freezing on spectroscopic properties of human plasma using fluorescence spectroscopy. 
Patients, materials and methods. The study group consisted of patients admitted to the Department of Cardiology 
and Internal Medicine at the University Hospital in Bydgoszcz, due to a preliminary diagnosis of acute coronary 
syndrome. The overall group comprised 27 patients. From each patient, 4 ml of blood was taken to obtain 
plasma that was used for further examination. In order to measure plasma spectroscopic properties, a Hitachi 
F-7000 spectrofluorimeter was used. The received results were analysed and evaluated with Origin 9.0 (OriginLab). 
Results. Spectroscopic analysis of human plasma before and after freezing allowed us to divide plasma 
samples into three different subgroups, depending on their fluorescent properties. The first subgroup 
consisted of plasma samples, which showed entirely differently in spectroscopic analysis after one week 
of deep-freezing. The second subgroup of plasma samples showed partial changes in the measurements 
of autofluorescence, and in the third subgroup freezing-resistant plasma samples were included. 
Conclusions. It seems that the process of deep-freezing could affect the autofluorescent properties of 
human plasma proteins. The explanation of the specific mechanisms responsible for the change of plasma 
fluorescent properties during the process of deep-freezing requires further elucidation.
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Introduction
Fluorescence-based techniques are powerful and 
valuable tools for studying biological materials. They 
provide information on the structure of biomolecules 
and the mechanism of their action. Fluorescence spec-
troscopy is one of the fluorescence-based techniques 
which measures fluorescence from a sample containing 
components such as proteins, nucleic acids and other 
substances which can emit autofluorescence. Proteins 
have the largest contribution in the effect of autofluores-
cence in biological materials. Human plasma consists 
of approximately 700 core proteins, as well as their 
precursors, metabolites, their glycosylated and phos-
phorylated forms, and the products of post-translational 
modifications. This indicates that the plasma proteome 
contains several dozen thousands of molecular forms of 
classic proteins. Hence, the protein profile (proteome) 
may differ depending on the metabolic pathways, indi-
vidual features, and different environmental conditions.
In their pioneering work, Teale et al. reported 
that proteins are capable of emitting luminescence 
after excitation by ultraviolet light. The fluorescence 
properties of proteins are connected to the presence 
of aromatic amino acids in their polypeptide chains, 
such as tryptophan, tyrosine and phenylalanine [1, 2]. 
Tryptophan is the dominant fluorophore of the proteins 
despite the small number of its residues in proteins, 
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which is caused by the high level of metabolic expense 
of its synthesis. Changes in the emission spectra of 
tryptophan often occur as a consequence of subunit 
association, conformational transitions, substrate bind-
ing and denaturation [3, 4].
Deep-freezing (at –80°C) of human plasma is a com-
mon storage method, even for a long time, assuming 
that at such a low temperature all biochemical process-
es are essentially reduced or inhibited. The aim of this 
study was to evaluate the influence of deep-freezing on 
autofluorescent properties of human plasma by means 
of fluorescence spectroscopy.
Patients, materials and methods
Study group
The study group consisted of patients admitted to 
the Department of Cardiology and Internal Medicine 
in University Hospital no 1 in Bydgoszcz due to a pre-
liminary diagnosis of acute coronary syndrome. Every 
patient received thorough information about the study 
and gave their written consent. The overall group com-
prised 27 patients, mean age 61 ± 14 years — 22 men 
(81.5%), mean age 59.6 ± 14.1 years, and five women 
(18.5%), mean age 64.6 ± 14.2 years. From each pa-
tient, a 4 ml blood sample was taken for examination. 
Methods
In order to measure plasma spectroscopic prop-
erties, a Hitachi F-7000 spectrofluorimeter was used. 
The measurements were made only in specified 
conditions which were determined on the basis of our 
earlier preliminary experiments. Shortly afterwards, 
comprehensive measurements using human plasma 
were performed. Then, conditions were chosen at which 
the autofluorescence was the highest and the most 
characteristic. The obtained results were analysed and 
evaluated with Origin 9.0 (OriginLab). 
Measurement procedure
The plasma was obtained by spinning fresh blood 
collected in the tubes containing EDTA in standard 
conditions. Plasma samples were aliquoted in two 
small tubes. In the first sample, the spectroscopic 
measurements were performed within three hours. The 
second plasma sample was frozen at –80°C for more 
than one week. Thawing of samples was performed 
in a few steps according to good laboratory practice. 
In the first stage, the plasma was placed in –20°C for 
0.5 h, thereafter in 4°C for 0.5 h. Plasma samples were 
kept at room temperature for 0.5 h before performing 
the measurements. For the purpose of spectroscopic 
measurements, 300 µL of plasma was taken. 
The autofluorescence signals of the thin layers 
(2 mm) of plasma specimens, placed between two 
quartz plates, were measured in the spectrofluorimeter 
at particular experimental geometry and at spectroscop-
ic conditions, selected from independent (preliminary) 
measurements. The autofluorescence emission and 
excitation spectra were collected at front-face exci-
tation-detection conditions, i.e. the same side of the 
sample was probed in the autofluorescence excitation 
and detection processes. The angle between the normal 
to the sample and the direction of exciting light propaga-
tion was set to about 60° in order to reduce the intensity 
of the scattered exciting light. The emission spectra 
were collected at the excitation wavelengths l = 320 nm, 
l = 340 nm, l = 360 nm, l = 380 nm, l = 400 nm, 
l = 450nm, while the excitation spectra were measured 
at the fluorescence detection wavelengths l = 380 nm, 
l = 400 nm, l = 430 nm, l = 450 nm, l = 500 nm. 
Statistical analysis
According to the Shapiro-Wilk test, the investigated 
continuous variables were non-normally distributed, 
therefore, they were reported as medians and interquartile 
ranges (IR). For comparisons between two groups, the 
Mann-Whitney unpaired rank sum test was used. Cate-
gorical variables were expressed as a number of patients 
presenting the given feature and a percentage of patients in 
the analysed group. Categorical variables were compared 
using the c2 test with the Yates’ correction or Fisher’s exact 
test depending on the number of observations. Differ-
ences were considered significant at p < 0.05. P values 
of ≥ 0.05 and < 0.10 were considered as a trend towards 
significance. The statistical analysis was carried out using 
the Statistica 10.0 package (StatSoft, Tulsa, OK, USA). 
Results
Spectroscopic analysis of the human plasma samples 
before and after freezing allowed us to split the patients 
into three different groups with respect to the differences 
in autofluorescence emission spectra (subgroups A, B 
and C), and also into three different groups with respect 
to the differences in autofluorescence excitation spectra 
(subgroups A’, B’ and C’) (Tabs. 1 and 2). Taken together, 
two sets of three subgroups of autofluorescence spectra 
were distinguished. The clinical characteristics of patients 
from all six subgroups are presented in Table 3. 
The first subgroups (A and A’) of both sets consisted 
of plasma samples which featured entirely differently in 
spectroscopic analysis after one week of deep-freezing. 
By ‘entirely different’ spectroscopic properties, we mean: 
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Table 1. Emission spectra: A — group of the plasma sam - 
ples, which were signalised entirely differently after deep 
freezing, B — group of the plasma samples, which were 
signalised partially differently after deep freezing, C — group  
of the plasma samples, which were freezing-resistant
A 1 2 9 12 21 19%
B 5 7 11 17 18 19 20 22 23 25 26 27 44%
C 3 4 6 8 10 13 14 15 16 24 37%
Table 2. Excitation spectra: A’ — group of the plasma 
samples, which were signalised entirely differently after deep  
freezing, B’ — group of the plasma samples, which were 
signalised partially differently after deep-freezing, C’ — group 
of the plasma samples, which were freezing-resistant
A’ 5 6 7 8 9 10 14 15 16 17 18 22 23 26 27 55%
B’ 1 2 3 12 13 19 20 21 30%
C’ 4 11 24 25 15%
Table 3. Clinical characteristics of the whole group and comparison of the three subgroups with respect to the 




















Men 22 (81.5%) 4 (80.0%) 8 (66.7%) 10 (100.0%) NS 0.963 NS
Age 63.0 (49.0–72.0) 49.0 (48.0–61.0) 63.0 (49.0–76.0) 59.0 (53.0–67.0) NS NS NS
Confirmed ACS 22 (81.5%) 5 (100.0%) 8 (66.7%) 9 (90.0%) NS NS NS
HyperteNSion 16 (59.3%) 3 (60.0%) 7 (58.3%) 6 (60.0%) NS NS NS
Diabetes mellitus 9 (33.3%) 1 (20.0%) 3 (25.0%) 5 (50.0%) NS NS NS
Dyslipidaemia 11 (40.7%) 2 (40.0%) 5 (41.7%) 4 (40.0%) NS NS NS
Smoking 16 (59.3%) 3 (60.0%) 6 (50.0%) 7 (70.0%) NS NS NS
Heart failure 10 (37.0%) 1 (20.0%) 5 (41.7%) 4 (40.0%) NS NS NS
Previous ACS 7 (25.9%) 1 (20.0%) 3 (25.0%) 3 (30.0%) NS NS NS
Leukocytes (G/l) 10.1 (7.0–13.6) 9.2 (7.8–10.1) 9.6 (6.4–11.9) 12.7 (10.3–14.0) NS NS NS
Erythrocytes (T/l) 4.7 (4.5–4.9) 4.9 (4.9–5.2) 4.5 (4.3–4.7) 4.8 (4.6–5.0) 0.051 0.081 NS
Haemoglobin (g/dl) 14.0 (13.0–15.0) 15.2 (14.9–15.2) 13.7 (12.1–14.3) 14.1 (13.8–15.0) 0.004 0.059 NS
Haematocrit (%) 42.0 (40.0–44.0) 44.8 (44.1–45.7) 40.9 (37.2–42.7) 41.9 (40.7–44.6) 0.0097 NS NS
MCV (fl) 89.0 (87.0–92.0) 90.7 (88.7–91.6) 90.7 (85.1–93.5) 88.0(87.3–91.2) NS NS NS
MCH (pg) 30.0 (29.0–31.0) 30.7 (29.5–31.5) 30.7 (28.7–31.4) 29.8 (28.7–30.1) NS NS NS
MCHC (g/dl) 33.4 (32.2–33.9) 33.8 (33.3–34.4) 33.4 (32.9–33.8) 33.5 (32.7–33.7) NS NS NS
Platelets (G/l) 208 (159.0–237.0) 208.0 (159.0–237.0) 204.0 (156.5–237.0) 212.0 (195.0–236.0) NS NS NS
RDW-SD (fl) 45.0 (43.0–46.0) 44.7 (43.0–46.0) 43.0 (41.2–45.4) 45.5 (43.7–46.1) NS NS NS
RDW–CV (%) 14.0 (13.0–14.0) 13.6 (13.5–14.1) 13.5 (13.1–14.1) 14.0 (13.4–14.5) NS NS NS
PDW (fl) 13.0 (12.0–15.0) 14.1 (11.7–15.0) 13.8 (12.4–14.7) 12.7 (12.2–13.1) NS NS NS
MPV (fl) 11.0 (11.0–12.0) 11.6 (10.1–12.0) 10.9 (10.4–11.5) 10.8 (10.5–10.9) NS NS NS
P-LCR (%) 32.0 (29.0–36.0) 36.7 (26.6–39.0) 32.8 (28.6–35.6) 30.5 (28.6–32.1) NS NS NS
PCT (%) 0.2 (0.2–0.3) 0.3 (0.2–0.3) 0.2 (0.2–0.3) 0.2 (0.2–0.3) NS NS NS
Total cholesterol (mg/dl) 173.5 (151.0–222.0) 198.0 (152.0–244.0) 153.0 (147.0–197.0) 181.0 (165.0–239.0) NS NS NS
HDL cholesterol (mg/dl) 48.0 (37.0–56.0) 53.0 (50.0–64.0) 41.0 (35.0–56.0) 44.0 (40.0–56.0) NS NS NS
Triglycerides (mg/dl) 105.5 (66.0–128.0) 147.0 (66.0–157.0) 85.0 (64.0–123.0) 106.0 (79.0–136.0) NS NS NS
LDL cholesterol (mg/dl)113.0 (78.0–150.0) 125.0 (76.0–168.0) 96.0 (72.0–135.0) 118.0 (99.0–168.0) NS NS NS
Troponin I (ng/ml) 0.7 (0.1–8.5) 0.3 (0.1–1.0) 1.0 (0.1–8.5) 2.2 (0.1–12.2) NS NS NS
Creatinine (mg/dl) 0.9 (0.8–1.3) 0.8 (0.8–0.8) 0.9 (0.8–1.2) 1.0 (0.8–1.3) NS NS NS
Sodium (mmol/l) 140.0 (139.0–141.0) 139.8 (139.8–140.6) 140.8 (139.0–143.2) 140.0 (138.1–141.1) NS NS NS
Potassium (mmol/l) 5.0 (4.0–5.0) 4.8 (4.3–5.0) 4.4 (3.8–4.6) 4.4 (3.7–4.6) NS NS NS
Chloride (mmol/l) 104.0 (103.0–108.0) 104.5 (104.2–105.8) 105.6 (103.8–108.4) 103.6 (100.1–109.7) NS NS NS
Glucose (mg/dl) 110.5 (99.0–154.0) 106.5 (94.0–127.0) 109.0 (100.0–128.0) 151.5 (91.0–159.0) NS NS NS
ACS — acute coronary syndrome; HDL — high density lipoprotein; INR — international normalised ratio; LDL — low density lipoprotein; MCH 
— mean corpuscular haemoglobin; MCHC — mean corpuscular haemoglobin concentration; MCV — mean corpuscular volume; MPV — mean 
platelet volume; NS — non significant; PCT — plateletcrit; P-LCR — platelet large cell ratio; PDW — platelet distribution width; RDW-CV — red 
blood cell distribution width coefficient variation; RDW-SD — red blood cell distribution width standard deviation
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Table 4. Clinical characteristics of the whole group and comparison of the three subgroups with respect to the 




















Men 22 (81.5%) 11 (73.3%) 7 (87.5%) 4 (100.0%) NS NS NS
Age 63.0 (49.0–72.0) 54.0 (45.0–70.0) 62.0 (51.0–76.0) 67.5 (65.0–70.0) NS NS NS
Confirmed ACS 22 (81.5%) 10 (66.7%) 8 (100.0%) 4 (100.0%) NS NS NS
Hypertension 16 (59.3%) 8 (53.3%) 5 (62.5%) 3 (75.0%) NS NS NS
Diabetes mellitus 9 (33.3%) 5 (33.3%) 2 (25.5%) 2 (50.0%) NS NS NS
Dyslipidaemia 11 (40.7%) 6 (40.0%) 3 (37.5%) 2 (50.0%) NS NS NS
Smoking 16 (59.3%) 10 (66.7%) 5 (62.5%) 1 (25.0%) NS NS NS
Heart failure 10 (37.0%) 5 (33.3%) 2 (25.5%) 3 (75.0%) NS NS NS
Previous ACS 7 (25.9%) 5 (33.3%) 0 2 (50.0%) NS NS NS
Leukocytes (G/l) 10.1 (7.0–13.6) 10.1 (7.0–13.6) 11.4 (8.3–13.3) 9.1 (5.7–13.2) NS NS NS
Erythrocytes (T/l) 4.7 (4.5–4.9) 4.6 (4.5–4.9) 4.7 (4.5–5.0) 4.9 (3.8–5.0) NS NS NS
Haemoglobin (g/dl) 14.0 (13.0–15.0) 14.0 (12.1–14.7) 14.6 (13.9–15.0) 14.0 (11.1–14.6) NS NS NS
Haematocrit (%) 42.0 (40.0–44.0) 41.7 (37.9–43.3) 43.8 (40.9–45.0) 41.5 (34.0–43.1) NS NS NS
MCV (fl) 89.0 (87.0–92.0) 89.4 (86.4–92.2) 91.0 (88.2–91.8) 86.4 (84.0–95.3) NS NS NS
MCH (pg) 30.0 (29.0–31.0) 30.1 (28.7–31.0) 30.3 (29.2–31.2) 29.2 (28.3–31.0) NS NS NS
MCHC (g/dl) 33.4 (32.2–33.9) 33.5 (33.3–34.2) 33.3 (32.7–33.8) 33.5 (32.4–33.8) NS NS NS
Platelets (G/l) 208 (159.0–237.0) 207.0 (178.0–255.0) 211.5 (153.5–234.5) 191.0 (153.0–228.5) NS NS NS
RDW-SD (fl) 45.0 (43.0–46.0) 43.1 (41.6–45.5) 45.7 (43.8–47.1) 49.6 (43.3–54.8) NS NS 0.035
RDW-CV (%) 14.0 (13.0–14.0) 13.4 (13.1–14.2) 14.0 (13.6–14.4) 15.0 (13.9–16.2) NS NS NS
PDW (fl) 13.0 (12.0–15.0) 12.8 (12.2–13.8) 15.0 (13.0–15.0) 12.9 (11.5–15.4) 0.071 NS NS
MPV (fl) 11.0 (11.0–12.0) 10.7 (10.5–11.0) 11.6 (10.9–11.9) 10.9 (10.2–12.0) 0.0109 NS NS
P-LCR (%) 32.0 (29.0–36.0) 30.2 (28.3–33.0) 36.3 (32.1–40.0) 31.3 (26.2–38.9) 0.016 NS NS
PCT (%) 0.2 (0.2–0.3) 0.2 (0.2–0.3) 0.3 (0.2–0.3) 0.2 (0.2–0.2) NS NS NS
Total cholesterol  
(mg/dl)
173.5 (151.0–222.0) 165.0 (137.0–222.0) 191.0 (167.0–221.0) 160.5 (137.0–205.0) NS NS NS
HDL cholesterol  
(mg/dl)
48.0 (37.0–56.0) 46.5 (38.0–56.0) 51.5 (40.5–64.5) 39.0 (34.0–48.5) NS NS NS
Triglycerides  
(mg/dl)
105.5 (66.0–128.0) 80.0 (64.0–126.0) 124.5 (105.5–152.0) 82.5 (79.0–100.0) NS NS NS
LDL cholesterol  
(mg/dl)
113.0 (78.0–150.0) 101.0 (71.0–150.0) 120.0 (102.0–155.0) 110.5 (84.0–150.0) NS NS NS
Troponin I (ng/ml) 0.7 (0.1–8.5) 1.6 (0.1–9.4) 0.4 (0.1–2.6) 0.3 (0.2–30.0) NS NS NS
Creatinine (mg/dl) 0.9 (0.8–1.3) 1.0 (0.8–1.3) 0.8 (0.8–1.1) 0.9 (0.8–1.7) NS NS NS
Sodium (mmol/l) 140.0 (139.0–141.0) 140.9 (138.1–143.2) 140.3 (139.8–140.7) 139.5 (136.7–141.8) NS NS NS
Potassium (mmol/l) 5.0 (4.0–5.0) 4.3 (3.7–4.6) 4.5 (4.1–4.8) 5.1 (4.1–5.9) NS NS NS
Chloride (mmol/l) 104.0 (103.0–108.0) 105.3 (100.1–109.7) 104.3 (103.6–105.2) 105.6 (103.2–108.6) NS NS NS
Glucose (mg/dl) 110.5 (99.0–154.0) 111.0 (100.0–159.0) 108.0 (99.0–143.0) 125.0 (93.5–169.0) NS NS NS
ACS — acute coronary syndrome; HDL — high density lipoprotein; INR — international normalised ratio; LDL — low density lipoprotein; MCH 
— mean corpuscular haemoglobin; MCHC — mean corpuscular haemoglobin concentration; MCV — mean corpuscular volume; MPV — mean 
platelet volume; NS — non significant; PCT — plateletcrit; P-LCR — platelet large cell ratio; PDW — platelet distribution width; RDW-CV — red 
blood cell distribution width coefficient variation; RDW-SD — red blood cell distribution width standard deviation
5–6 changes in measurements using emission spectra 
or 4-5 changes in measurements using excitation spec-
tra. During all the measurements, the following changes 
were observed: a shift of the autofluorescence spectra 
(Fig. 1), and a change of shapes of the spectra (Fig. 2). 
Only three patients’ plasma samples showed entirely 
differently after deep-freezing when analysing the results 
of both emission and excitation spectra.
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The second group (subgroups B and B’) of plasma 
samples showed partial changes in the measure-
ments of autofluorescence. By ‘partial changes’ we 
mean: 2–4 changes in measurements using emis-
sion spectra or 3–4 changes in measurements using 
excitation spectra. Modifications such as: a shift of 
the autofluorescence spectra (Fig. 1), and a change 
in the shape of the spectra (Fig. 2), were observed. 
Modifications were complex and diversified in different 
patients (Tab. 3). 
The third group (subgroups C and C’) of samples 
was freezing-resistant. Any significant changes com-
paring plasma samples before and after deep-freezing 
were found in spectroscopic analysis (Fig. 3). By ‘not 
significant changes’ we mean at most one accidental 
change in the measurements using emission or at 
most one change in the measurements using excita-
tion spectra. Only two patients’ plasma samples were 
freezing-resistant and presented the same comparable 
results of both emission and excitation spectra.
In addition, we also checked, in a small group of 
three patients, whether incubation at 37°C influences 
the plasma spectroscopic properties. Therefore, after 
thawing, the plasma samples of three randomly se-
lected patients were warmed up to 37°C, which is the 
normal body temperature. The spectroscopic measure-
ments of the plasma samples were made after 0.5 h in 
37°C, then after 1 h and 1.5 h in 37°C. This experiment 
demonstrated that spectroscopic characterisation of 
the deep-frozen sample was the same when the plasma 
was kept at room temperature as it was after incuba-
tion at 37 degrees (Fig. 4). Probably, spectroscopic 
changes which were observed after deep-freezing 
are connected to irreversible damage caused by the 
freezing process. This hypothesis requires further in-
vestigation.
Discussion
The process of deep-freezing may affect the auto-
fluorescent spectra of some human plasma proteins. It 
is now well established that proteins undergo cold de-
naturation at low temperatures as well as at high tem-
peratures [5, 6]. The majority of proteins are sensitive to 
low temperatures which may cause loss of their native 
structure/conformation and enhancement of visibility of 
their non-polar residues. Water molecules tend to form 
ice-like cages around non-polar molecules. This spe-
cial structure, known as a clathrate cage, is associated 
with thermodynamic changes [7, 8]. Compared to heat 
denaturation, cold denaturation is generally reversible, 
Figure 1. Excitation spectra from fresh plasma and plasma 
after deep freezing (sample 22; l = 400 nm)
Figure 2. Excitation spectra from fresh plasma and plasma 
after deep freezing (sample 3; l = 400 nm) 
Figure 3. Excitation spectra from fresh plasma and plasma 
after deep freezing (sample 4; l = 400 nm)
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so proteins can regain their biological functionality. 
However, some proteins are particularly sensitive to 
low temperatures, so they can lose their function ir-
reversibly as well. 
The formation of ice crystals still remains unex-
plained. This process occurs upon ice formation via 
nucleation and crystal growth from supercooled water. 
There are three stages of this process: chemical dif-
fusion for water molecule transportation, the surface 
kinetic phase for hydrogen bonds formation, and the 
heat conduction for heat releasing and diffusing. In fact, 
the ice crystals formation process is heterogeneous in 
most cases and may be influenced by many different 
factors. Until now, the two main theories devised to ex-
plain this process can be classified as ‘thermodynamic 
approximation’ and ‘molecular simulation’ [9]. Given 
the fact that the formation of ice crystals is not fully 
understood, it can be assumed that it may damage the 
structure of proteins, which have autofluorescent prop-
erties, as well as other proteins, which also contribute 
to the fluorescence of human plasma. 
Probably, during freezing, some proteins which are 
able to emit autofluorescence are prone to conforma-
tional and/or structural changes. The explanation of 
the specific mechanism responsible for the change 
of the plasma fluorescent properties during the pro-
cess of deep-freezing is of significant importance to 
confirm the reliability of studies using frozen plasma 
samples. One supposed mechanism involves con-
formational changes, which may appear during the 
temperature changes. 
Because of the complex nature of the fluores-
cence phenomenon, all kind of changes concerning 
the autofluorescent properties of proteins may affect 
the fluorescence of the whole plasma sample [10]. 
These changes, which could include reallocation of 
maximum spectra (Fig. 1) and change of shapes of 
autofluorescence spectra (Fig. 2), may be caused by 
environmental modification of the particular protein. 
Accordingly, the structure or conformational changes 
in some proteins may change fluorescence, something 
that puts off fluorescence in certain proteins and puts in 
fluorescence in other proteins, simultaneously. It may 
significantly convert shapes of the autofluorescence 
spectra. 
The differences in the spectroscopic properties of 
plasma among patients may be due to individual vari-
ability. Plasma is not only a biological material but also 
represents a proteome, which is specific for a given 
patient. It usually contains a vast amount of proteins 
or their modified forms. There are many factors which 
may influence plasma proteome such as: age, sex, 
diet, stress, diseases and many others [11]. Because 
of these, the analysis of plasma specific protein com-
Figure 4. Excitation spectra from fresh plasma and plasma after deep freezing (sample 17; l = 400 nm)
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position without prior separation of the most abundant 
proteins is very difficult, or even impossible. 
It is crucial to continue further investigation in this 
field. The most significant step is the fractionation of 
human plasma in order to check the autofluorescent 
properties of different protein fractions. It is also 
essential to attempt to recognise the components 
of appropriate autofluorescence spectra. The most 
useful available method to separate proteins is 
two-dimensional electrophoresis [12]. Thereafter, 
analysis with MALDI-TOF, which is an ionisation 
technique used in mass spectrometry, will be the next 
step in research. 
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